Pieris business strategy

Pieris is exploiting its extensive intellectual property in the engineering of novel proteins by focusing on innovative approaches to the custom design of drugs and diagnostic tools.

Pieris recognizes that the full commercial potential of its proprietary Anticalin® technology platform cannot be realized in isolation. The company therefore places significant value on its current alliances, the potential to maximize the value of those alliances and the opportunity to create new partnerships in the future.

Partnership is highly important to Pieris primarily:

• to enable us to combine complementary capabilities and expertise with other companies, to create value and ultimately to realize our vision as a drug discovery and development company
• to balance our research efforts between proprietary and partnered programs, allowing us to manage the risks and costs of drug discovery more effectively, and to share more fully in the rewards
  

The company applies the same fundamental principle to its partnerships as it does to its proprietary programs: to apply its technology and know-how creatively and appropriately, bringing innovation to the challenge of human diseases in areas of most significant medical need.